small-molecule inhibitor aberrant transcription factor cbf beta-smmhc delays leukemia mice 
acute myeloid leukemia aml common form adult leukemia transcription factor fusion cbf beta-smmhc core binding factor beta smooth-muscle myosin heavy chain expressed aml chromosome inversion inv16p13q22 outcompetes wild-type cbf beta binding transcription factor runx1 deregulates runx1 activity hematopoiesis induces aml current inv16 aml treatment nonselective cytotoxic chemotherapy results good initial response limited long-term survival report development protein-protein interaction inhibitor ai-- selectively binds cbf beta-smmhc disrupts binding runx1 ai-- restores runx1 transcriptional activity displays favorable pharmacokinetics delays leukemia progression mice treatment primary inv16 aml patient blasts ai-- triggers selective cell death data suggest direct inhibition oncogenic cbf beta-smmhc fusion protein may effective therapeutic approach inv16 aml provide support transcription factor targeted therapy cancers 
